.png){kind=icon}
.png){kind=icon}
Return
A Phase 1 Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Zerlasiran in Japanese Participants
.png){kind=icon}
PRE
AI
F
H
R
O
R
DOI：10.5551/jat.66214.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Aim: Zerlasiran is an N-acetylgalactosamine-conjugated small interfering RNA that targets lipoprotein(a), a risk factor for atherosclerosis and calcific aortic stenosis. Zerlasiran has not been studied in Japanese participants previously. Method: This was an open-label, single-dose trial that enrolled 18 adult participants with lipoprotein(a) levels >= 70 nmol/L at a single site in Japan to evaluate subcutaneous doses of zerlasiran (30 mg, 100 mg, and 300 mg) in three ascending-dose cohorts. The participants were monitored for 150 days post-dose to assess the systemic pharmacokinetics, pharmacodynamics (lipoprotein (a) and lipid biomarkers), and safety. Results: Following dosing, median Tmax was reached at 5 hours with plasma concentrations gradually declining to undetectable levels by 36 hours, with t1/2 approximately 4 hours. Both Cmax and AUC0-inf increased in a dosedependent manner. The maximum median (interquartile range [IQR]) percent reduction in lipoprotein (a) in the 30 mg, 100 mg, and 300 mg cohorts were-72.8% (-79.7%,-67.1%), 88.8% (-89.5%,-84.7%), and-97.8% (-98.6,-96.9%), respectively, between days 30 and 60, with a sustained effect observed at 150 days at all dose levels. All adverse events were mild and self-limiting. Conclusion: Zerlasiran was well tolerated with no significant safety findings observed at any dose level. A typical pharmacokinetic profile expected of an N-acetylgalactosamine-conjugated small interfering RNA, coupled with a potent and sustained reduction in lipoprotein(a), was observed in Japanese participants. No adverse effects on either the liver or kidney function were observed.
Keywords:
Lipoprotein(a)
Zerlasiran
Pharmacokinetics
Safety
Small interfering RNA
Journal
J
IF:
2.8
Papers:
2.4K
Citations:
4.7K
Organization
Cited Papers